Aneurysmal Subarachnoid Hemorrhage

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
erythropoietin betaPhase 21 trial
Active Trials
NCT00140010Completed80Est. Mar 2007
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
Diben 1.5 kcal HPN/A1 trial
Active Trials
NCT02503527Terminated28Est. Sep 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rocheerythropoietin beta
Fresenius KabiDiben 1.5 kcal HP

Clinical Trials (2)

Total enrollment: 108 patients across 2 trials

NCT00140010Rocheerythropoietin beta

Erythropoietin Therapy for Subarachnoid Hemorrhage

Start: Apr 2005Est. completion: Mar 200780 patients
Phase 2Completed
NCT02503527Fresenius KabiDiben 1.5 kcal HP

Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy

Start: Aug 2015Est. completion: Sep 201828 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space